pioglitazone has been researched along with Experimental Neoplasms in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grommes, C | 1 |
| Landreth, GE | 1 |
| Sastre, M | 1 |
| Beck, M | 1 |
| Feinstein, DL | 1 |
| Jacobs, AH | 1 |
| Schlegel, U | 1 |
| Heneka, MT | 1 |
1 other study available for pioglitazone and Experimental Neoplasms
| Article | Year |
|---|---|
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Topics: Administration, Oral; Animals; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Bromodeoxyuri | 2006 |